Tuberculosis (TB) and leprosy are mycobacterial infections caused by and respectively. These diseases continue to be endemic in developing countries where the cost of new medicines presents major challenges. The situation is further exacerbated by the emergence of resistance to many front-line antibiotics. A priority now is to design new antimycobacterials that are not only effective in combatting the diseases but are also less likely to give rise to resistance. In both these respects understanding the structure of drug targets in and is crucial. In this review we describe structure-guided approaches to understanding the impacts of mutations that give rise to antimycobacterial resistance and the use of this information in the design of new medicines.
BT - Frontiers in genetics C1 - https://www.ncbi.nlm.nih.gov/pubmed/33101362 DA - 01/2020 DO - 10.3389/fgene.2020.00965 J2 - Front Genet LA - eng N2 -Tuberculosis (TB) and leprosy are mycobacterial infections caused by and respectively. These diseases continue to be endemic in developing countries where the cost of new medicines presents major challenges. The situation is further exacerbated by the emergence of resistance to many front-line antibiotics. A priority now is to design new antimycobacterials that are not only effective in combatting the diseases but are also less likely to give rise to resistance. In both these respects understanding the structure of drug targets in and is crucial. In this review we describe structure-guided approaches to understanding the impacts of mutations that give rise to antimycobacterial resistance and the use of this information in the design of new medicines.
PY - 2020 EP - 965 T2 - Frontiers in genetics TI - Genomics, Computational Biology and Drug Discovery for Mycobacterial Infections: Fighting the Emergence of Resistance. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498718/pdf/fgene-11-00965.pdf VL - 11 SN - 1664-8021 ER -